GKT137831

DRUG4 trials

Sponsors

Calliditas Therapeutics AB, University of Alabama at Birmingham

Conditions

Idiopathic Pulmonary FibrosisPhase 1Primary Biliary CirrhosisType 2 Diabetes Mellitus With Diabetic Nephropathy

Phase 1

Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

CompletedNCT03740217

Calliditas Therapeutics ABPhase 1

Start: 2018-12-19End: 2019-02-06Updated: 2022-06-30

Phase 2

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

CompletedNCT02010242

Calliditas Therapeutics ABType 2 Diabetes Mellitus With Diabetic Nephropathy

Start: 2013-10-31End: 2015-03-31Updated: 2025-02-28

Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.

CompletedNCT03226067

Calliditas Therapeutics ABPrimary Biliary Cirrhosis

Start: 2017-06-26End: 2019-04-11Updated: 2022-06-29

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis

CompletedNCT03865927

University of Alabama at BirminghamIdiopathic Pulmonary Fibrosis

Start: 2020-09-07End: 2024-11-30Updated: 2026-05-11

Related Papers

Breaking Grounds: A Comprehensive Analysis of Cutting-Edge Treatments for Primary Biliary Cirrhosis/Primary Biliary Cholangitis With Futuristic Treatments.

2025-02-24

Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial

Hepatology Communications2023-02-2031 citations

Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan.

2020-06-039 citations